Has Saul Karpen received payments from drug or device companies?

Yes. Drug and device makers reported $51,057 in general payments to Saul Karpen across 51 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Saul Karpen did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Saul Karpen come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Saul Karpen

Gastroenterology · Atlanta, GANPI 1427138783

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $33,843 of the $51,057 with a category attached, or 66.3%. 8 manufacturers reported payments, led by Mirum Pharmaceuticals, Inc. at 45.0% of the total. Reporting peaked in 2023 at $15,710 and has fallen 99.4% since, to $88 in 2025. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,057in general payments, 2019–2025

Across 51 payments — averaging $1001.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mirum Pharmaceuticals, Inc.$23K
Intercept Pharmaceuticals, Inc.$16K
Albireo Pharma, Inc.$5K
Ipsen Bioscience Inc.$3K
Vertex$3K
Madrigal Pharmaceuticals$136
plus $135 from 2 others

$317,290in research payments, 2019–2025

Across 29 payments — averaging $10,941 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Albireo Pharma, Inc.$199K
Mirum Pharmaceuticals, Inc.$118K

What the payments were for

Consulting fees$33,84366%
Speaking & faculty fees$8,91417%
Travel & lodging$7,23614%
Food & beverage$1,0642%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mirum Pharmaceuticals, Inc.	24	$22,987
Intercept Pharmaceuticals, Inc.	13	$16,389
Albireo Pharma, Inc.	8	$5,247
Ipsen Bioscience Inc.	1	$3,364
Vertex	1	$2,800
Madrigal Pharmaceuticals	1	$136
Ipsen Innovation	1	$88
Siemens Medical Solutions USA, Inc.	2	$46

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Livmarli$16,691
OCALIVA$8,990
Bylvay$5,085
RESMETIROM$136

How this compares

$51,057 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia →

Other gastroenterology in Atlanta

Nitin GuptaAtlanta$1.1M
Cynthia RudertAtlanta$720K
Douglas WolfAtlanta$668K
Kavita KongaraAtlanta$492K
Girish AnandAtlanta$425K
Roshan ShresthaAtlanta$317K
Hetal KarsanAtlanta$314K
Marc SonenshineAtlanta$201K
Julia LiuAtlanta$163K
Huiming HonAtlanta$159K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →